PMLS picks new Chief Commercial Officer for fast-growing organization see more
Premier Medical Laboratory Services (PMLS) is announcing today Jeff Schmalz as their new Chief Commercial Officer. At PMLS, Jeff will be focusing on the major disciplines impacting lab growth including partnerships, product development, clinical outreach, sales infrastructure, customer service and marketing. With 35 years of experience in multiple healthcare organizations, he brings extensive knowledge in the diagnostics and reference lab markets.
In his latest role, he led the segment marketing and business development team responsible for integrating specialty labs, technology, and test launches that contributed to several hundred million in additional revenue growth. Jeff also oversaw the launching, branding, and commercializing of Lab Developed Tests (LTDS) over a period of 15 years for 25 test classes resulting in over $400M per year in revenue. He has founded, developed, and launched international partnerships to carry out his sales initiatives and maximize overall market share.
“I chose to work at Premier Medical Laboratory Services because they’re an innovative and nimble company with all of the components in place to make them a national leading specialty lab,” said Jeff Schmalz. “They lead with a forward-thinking approach to unmet needs within the healthcare industry and continually build on their capabilities to bring the most advanced medical diagnostics services for better patient outcomes…and that’s something I want to be a part of and advance forward.”
As a graduate and scholarship athlete from the University of Maryland, Jeff pursued an executive management MBA curriculum from the Kellogg School of Management. Since then, he has served as a board member for the Biomedical Marketing Association and successfully launched products at Abbot, Chiron, LabCorp, Digene, Bayer and Qiagen. He managed a team of 53 segment leaders, product managers, and marketing communication strategists by positive motivation, leading by example, and empowering them to make decisions and take initiative.
“We are at an integral phase in our growth here at Premier Medical Laboratory Services as a top lab with the mission to bring the most advanced diagnostics to our nation,” said Kevin Murdock, CEO and Founder of PMLS. “The level of talent and experience that Jeff Schmalz possesses will help us tremendously in fulfilling our vision of improving patient lives.”
ABOUT PREMIER MEDICAL LABORATORY SERVICES
Premier Medical Laboratory Services (PMLS), based in Greenville, South Carolina, is an advanced molecular diagnostics lab fully certified by top laboratory accrediting organizations, including CLIA and COLA. With the most advanced laboratory information systems (LIS) easy to read one-page test result reports are generated with higher accuracy and a customizable report for each client. PMLS prides itself on having some of the most rapid turnaround times for testing results in the industry. Their expansive testing menu includes Pharmacogenomics, COVID-19 testing, Advanced Cardiovascular Testing, Diabetes, Women's Wellness panels, Allergen Specific Ige Blood Testing, Toxicology, and a first of its kind predictive genetic test for type II diabetes, DIABETESPredict. For more information, please visit www.PreMedInc.com
Prisma aligns with Siemens Healthineers see more
Prisma Health is entering a 10-year partnership with German technology company Siemens to become more efficient and improve patient care, the companies announced June 22.
Prisma staff members will work with technology experts from the Siemens Healthineers division to evaluate how the company uses technology to treat patients, including the use of artificial intelligence.
Prisma Health, the state’s largest hospital system, needs to keep improving how it works as the challenges of health care, from rising costs to keeping a trained workforce, keep mounting, Prisma Health CEO Mark O’Halla said.
“We have to get better — better outcomes and cheaper,” O’Halla said.
One of the roles that technology can play is to make work more efficient for the staff, both through better systems and training, said Dave Pacitti, president for the Americas of Siemens Healthineers, the health care tech portion of the German engineering giant.
That should bring more time for clinical staff to treat patients, he said.
No financial terms of the 10-year partnership were disclosed, but Pacitti said it is his company’s largest partnership with a health care provider.
Artificial intelligence will be used to study how Prisma Health is treating patients by analyzing the collected data with no names of patients attached, O’Halla said.
AI also will be able to help care for individual patients, Pacitti said. One example: an AI system can work in the background as a doctor or other staff members examine computer images from a scan, looking to highlight areas on the image that that need more scrutiny.
The deal will include adding more modern diagnostic equipment from Siemens and making sure that the systems are deployed around the state in the most efficient way possible, O’Halla said.
For Siemens, the deal will provide direct clinical feedback on how its systems work in medical offices.
Prisma Health operates 18 hospitals, including the former Palmetto Health system in the Midlands. Headquartered in Greenville, it employs more than 30,000 staff members.
KIYATEC Advancing Functional Ex Vivo 3D Cell Culture Models that Reveal Response Dynamics to Immuno-Oncology DrugsKey evidence to be presented at AACR 2020 see more
KIYATEC, Inc. today announced that it will present data at the 2020 American Association for Cancer Research (AACR) Annual Meeting, June 22-24, revealing how its 3D cell culture models characterize ex vivo tumor response and immunoreactivity to immune checkpoint inhibitors (i.e. PD-1, PD-L1 inhibitors) in solid tumors. These emerging capabilities address a significant unmet need in both preclinical drug development and clinical decision-making in oncology.
PD-1/L1 inhibitors have experienced meteoric growth over the last decade, offering hope to hundreds of thousands of cancer patients every year in the US alone. However, typically no more than 25-30% of eligible cancer patients who receive PD-1/L1 inhibitors actually respond to them. Given that the direct costs associated with PD-1/L1 therapy can run into the hundreds of thousands of dollars per patient, KIYATEC believes that pre-treatment, patient-specific PD-1/L1 response prediction could one day offer clinicians, patients and payers a more objective basis for determining PD-1/L1 inhibitor patient eligibility vs. today’s commonly used population-based biomarkers.
Evidence presented by KIYATEC at AACR 2020 will highlight findings of the company’s ability to detect dose-dependent response to checkpoint blockade and corresponding correlation with immune cell activation in high-throughput ex vivo 3D tumor spheroid models. KIYATEC believes these recent advances may represent key building blocks toward the eventual development and validation of clinical assays capable of accurate pre-treatment, patient-specific prediction of response to immuno-oncology drugs.
“We’re constantly innovating and expanding the capabilities of our 3D cell culture technologies to reduce the cost and risk of preclinical drug development for our immuno-oncology customers,” said Matthew Gevaert, CEO of KIYATEC. “As we continue to make these advances in immuno-oncology drug response on higher-throughput platforms, we can begin to envision a time when such capability would inform clinical decision-making for cancer patients as well.”
KIYATEC’s poster presentations at AACR 2020 are as follows:
- Abstract: 7397 / Poster: 315 / Session: 3D & Tissue Recombinant Models / June 22-24
Title: PARP inhibition in combination with pembrolizumab enhances cytotoxicity in ovarian cancer patient-derived 3D spheroids
- Abstract: 7132 / Poster: 2244 / Session: Immune Checkpoints 2 / June 22-24
About KIYATEC, Inc.
KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company’s Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types. The company’s Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory. To learn more about KIYATEC, visit www.kiyatec.com.
South Carolina life sciences gets another huge boost with BD's $150 million investment in Sumter see more
Medical technology company creating 125 new jobs
COLUMBIA, S.C. - BD (Becton, Dickinson and Company), a leading global medical technology company, today announced a $150 million investment in its existing Sumter County manufacturing facility. The company is projected to create an additional 125 new jobs over the next several years.
Employing more than 65,000 associates worldwide, BD is one of the world's largest medical technology companies and supports health care providers in more than 190 countries. BD's Sumter County facility has been in operation since 1970, manufacturing blood collection devices that are critical to the health care industry.
Located at 1575 Airport Road in Sumter, S.C., BD's Sumter facility is actively hiring for the new positions, and interested applicants should visit www.bd.com/careers for more information.
The Coordinating Council for Economic Development has approved job development credits related to this project, as well as a $600,000 Set Aside grant to assist with the costs of road work and site preparation.
"For nearly 50 years, BD's Sumter facility has consistently delivered superior quality products, vital for our customers and their patients, through a talented and engaged workforce. We would like to thank TheLINK economic development alliance, Sumter Economic Development, the City of Sumter, Sumter County and the S.C. Department of Commerce for their continued support of BD and our employees as we continue to invest in the facility. We look forward to the ongoing success of our BD Sumter manufacturing team as they continue to advance the world of health." -BD Executive Vice President of Global Operations and Chief Supply Chain Officer Jim Borzi
"After opening in our state more than 40 years ago, we're thrilled that BD continues to grow and succeed here. This announcement once again demonstrates that South Carolina is a place where medical technology companies want to do business, and we welcome this new $150 million investment." -Gov. Henry McMaster
"Not only does our state excel in advanced manufacturing, we're also increasingly a top choice for companies in the life sciences sector. BD has been a strong member of Team South Carolina for decades, and we congratulate them on their ongoing success." -Secretary of Commerce Bobby Hitt
"BD has been a leading employer in this county since opening its doors in 1970. We are grateful for their continued investment in our community and our people." -Sumter County Council Chairman James McCain
"We have long-enjoyed BD as a key component in the fabric of our industrial portfolio. This investment demonstrates their trust in our leadership, their commitment to the success of their business and their belief in our ability to regenerate the talent needed to produce the quality of goods for which BD is known." -Sumter Economic Development Chairman Greg Thompson
FIVE FAST FACTS
- BD is investing in its existing Sumter County manufacturing facility.
- $150 million investment to create 125 new jobs.
- Employing more than 65,000 associates worldwide, BD is one of the largest medical technology companies in the world and supports health care providers in more than 190 countries.
- Located at 1575 Airport Road in Sumter, S.C., BD's facility manufactures blood collection devices for the health care industry.
BD is actively hiring for the new positions, and interested applicants should visit www.bd.com/careers for more information.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to better diagnose disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit www.bd.com.